Business
Gain Therapeutics Reports Financial Results for Second Quarter 2024 and Provides Corporate Update
Topline Results From MAD Phase 1 Study of GT-02287 on Track for August 2024 With Full Presentation at Upcoming Medical Conferences in Early Q4 2024 Initiation
About this update from Gain Therapeutics, Inc.
[{"type":"text","content":"Topline Results From MAD Phase 1 Study of GT-02287 on Track for August 2024 With Full Presentation at Upcoming Medical Conferences in Early Q4 2024 Initiation of Phase 1b Study of GT-02287 in Parkinson’s Disease Patients Anticipated in Q4 2024 BETHESDA, Md., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reports financial results for the quarter ended June 30, 2024, and provides a corporate update. “The second quarter of 2024 proved to be productive for Gain, as we made significant progress in advancing our lead candidate GT-02287,” said Gene Mack, Interim CEO and CFO of Gain. “We are encouraged by results to date, from both the SAD and MAD studies completed in the second quarter, demonstrating GT-02287’s favorable safety profile. As we eagerly await the full topline results from the MAD part of the study expected this month, we remain confident in the potential of GT-02287 to become a lead treatment for Parkinson’s disease in patients with or without a GBA1 mutation. We look forward to presenting our findings at medical conferences this fall and advancing GT-02287 into a Phase 1b study to evaluate its efficacy in actual Parkinson’s patients in the fourth quarter of 2024. Finally, we believe we are well-positioned to continue executing on our near-term clinical milestones, with the goal of delivering a life-changing therapy to patients in need.” Second Quarter 2024 and Recent Corporate Highlights Pipeline Updates Announced the completion of dosing in the Multiple Ascending Dose (MAD) portion of the Phase 1 trial of GT-02287, the Company’s lead candidate being evaluated for the treatment of Parkinson’s disease in patients with or without a GBA1 mutation;Announced positive results from the Single Ascending Dose (SAD) portion of the Phase 1 trial of GT-02287; andPresented preclinical data demonstrating an improvement in cognitive performance and activities of daily living with GT-02287 treatment in a mouse model of Parkinson’s disease in a late-breaking poster presentation at the Federation of European Neuroscience Societies (FENS) Forum 2024 held in Austria. Corporate Updates Announced appointment of Gene Mack as interim CEO and Chief...